| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/19/2005 | EP1497419A1 Nucleic acid molecule encoding a variant ddah 1 protein and uses thereof |
| 01/19/2005 | EP1497296A1 1,4 DIAZOCINO 7,8,1-hi INDOLE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS |
| 01/19/2005 | EP1497294A1 1,2,3,4,7,8-HEXAHYDRO-6 i H /i - 1,4 DIAZEPINO 6,7 ,1- i 1J /i QUINOLINE DERIVATIVES AS ANTIPSYCHOTIC AND ANTI OBESITY AGENTS |
| 01/19/2005 | EP1497293A1 (1,4)diazepino(6,7,1-ij)quinoline derivatives as anti psychotic and antiobesity agents |
| 01/19/2005 | EP1497291A2 Quinoline and aza-indole derivatives and their use as 5-ht6 ligands |
| 01/19/2005 | EP1497285A1 Benzoxazinone-derived compounds, their preparation und use as medicaments |
| 01/19/2005 | EP1497279A2 Substituted indoles and their use as 5ht-reuptake inhibitors and as 5ht ligands |
| 01/19/2005 | EP1497274A2 Terphenyl derivatives, preparation thereof, compositions containing same |
| 01/19/2005 | EP1497273A2 Hydroxamic acid derivatives |
| 01/19/2005 | EP1497272A2 Method of preparing amine stereoisomers |
| 01/19/2005 | EP1497271A1 Indane acetic acid derivatives and their use as pharmaceutical agents |
| 01/19/2005 | EP1497268A2 Nitric oxide donors, compositions and methods of use |
| 01/19/2005 | EP1497266A2 Quinoline derivatives and their use as 5-ht6 ligands |
| 01/19/2005 | EP1497263A1 Acyl-3-carboxyphenylurea derivatives, method for production and use thereof |
| 01/19/2005 | EP1497262A1 Acyl-4-carboxyphenylurea derivatives, method for production and use thereof |
| 01/19/2005 | EP1497260A1 Novel methoxybenzamide compounds for use in mch receptor related disorders |
| 01/19/2005 | EP1497258A1 Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine |
| 01/19/2005 | EP1497256A1 Substituted 1,5-diaminopentan-3-ol compounds |
| 01/19/2005 | EP1497247A2 Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses |
| 01/19/2005 | EP1497019A1 Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| 01/19/2005 | EP1496967A1 Therapeutic dry powder preparation |
| 01/19/2005 | EP1496940A2 Methods of treating diabetes using pde 11a inhibitors |
| 01/19/2005 | EP1496935A2 Insulin and igf-1 receptor agonists and antagonists |
| 01/19/2005 | EP1496926A1 Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| 01/19/2005 | EP1496924A2 Treatment of gastroparesis |
| 01/19/2005 | EP1496920A1 Pharmaceutical composition containing an extract from barleria prionitis linn and its process of preparation |
| 01/19/2005 | EP1496917A1 Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
| 01/19/2005 | EP1496914A1 (20S)-1a-HYDROXY-2a-METHYL AND 2&bgr;-METHYL-19-NOR-VITAM IN D sb 3 /sb AND THEIR USES |
| 01/19/2005 | EP1496910A1 Kinase inhibitors |
| 01/19/2005 | EP1496907A2 Tyrosine kinase inhibitors |
| 01/19/2005 | EP1496898A2 Tyrosine kinase inhibitors |
| 01/19/2005 | EP1496897A1 Tyrosine kinase inhibitors |
| 01/19/2005 | EP1496894A1 Angiogenesis inhibitors |
| 01/19/2005 | EP1496892A2 1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| 01/19/2005 | EP1496889A1 Stabilized ascorbic acid derivatives |
| 01/19/2005 | EP1496884A1 Association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases |
| 01/19/2005 | EP1496881A2 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance |
| 01/19/2005 | EP1496877A2 Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states |
| 01/19/2005 | EP1496873A2 Chewable soft capsule |
| 01/19/2005 | EP1496872A2 Functional foods containing a phospholipid-containing stable matrix |
| 01/19/2005 | EP1496863A2 Preparation and use of a stable formulation of allosteric effector compounds |
| 01/19/2005 | EP1496857A1 Aerosol containing a particulate active substance |
| 01/19/2005 | EP1496838A2 Substituted amides |
| 01/19/2005 | EP1496757A1 Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight |
| 01/19/2005 | EP1392366A4 Nuclear receptor-mediated introduction of a pna into cell nuclei |
| 01/19/2005 | EP1377574B1 6-phenylbenzonaphthyridines |
| 01/19/2005 | EP1368348B1 Novel 2,5-diazabicyclo(2.2.1)heptane derivatives |
| 01/19/2005 | EP1230244B1 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
| 01/19/2005 | EP1208104B1 Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 01/19/2005 | EP1200385B1 Crystals of the sodium salt of pravastatin |
| 01/19/2005 | EP1181271B1 Naphthalene ureas as glucose uptake enhancers |
| 01/19/2005 | EP0954282B1 Preparation of particles for inhalation |
| 01/19/2005 | CN1568374A Method for identifying compounds modulating reverse cholesterol transport |
| 01/19/2005 | CN1568365A Composition comprising a lactobacillus pentosus strain and uses thereof |
| 01/19/2005 | CN1568330A Glycosylphosphatidylinositol containing polypeptides |
| 01/19/2005 | CN1568323A Activator for peroxisome proliferator-activated receptor delta |
| 01/19/2005 | CN1568316A Activator for peroxisome proliferator-responsive receptor delta |
| 01/19/2005 | CN1568312A Biphenylcarboxamides useful as lipid lowering agents |
| 01/19/2005 | CN1568310A Heterocyclic inhibitors of glycogen synthase kinase GSK-3 |
| 01/19/2005 | CN1568207A 2-amino-6-(2, 4, 5-substituted-phenyl)-pyridines |
| 01/19/2005 | CN1568199A Drugs ameliorating hypo-HDL cholesterolemia |
| 01/19/2005 | CN1568196A Nutrient therapy for immuno-compromised patients |
| 01/19/2005 | CN1568195A Peptide YY and peptide YY agonists for treatment of metabolic disorders |
| 01/19/2005 | CN1568190A Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators |
| 01/19/2005 | CN1568185A Compounds effecting glucokinase |
| 01/19/2005 | CN1568181A Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| 01/19/2005 | CN1566128A Sugar charcoal glycoside isoflavone compound containing alkane amine group and alkoxy substitution, process and uses thereof |
| 01/19/2005 | CN1566127A Novel flavonoids |
| 01/19/2005 | CN1566126A Novel natural drug effective region |
| 01/19/2005 | CN1566109A Aldose reductase inhibitor, preparation method and use thereof |
| 01/19/2005 | CN1566086A Amino acid calcium chelate, preparation and application thereof |
| 01/19/2005 | CN1566077A Algal ammonia acid and functions thereof |
| 01/19/2005 | CN1565626A Nutrient agent |
| 01/19/2005 | CN1565625A Preparing process of insulin powder inhalant |
| 01/19/2005 | CN1565623A Calcitonin composition |
| 01/19/2005 | CN1565617A Nutrient healthy powder for decreasing blood sugar and resolving stagnation |
| 01/19/2005 | CN1565609A Chinese herbal medicine compositions and is usage |
| 01/19/2005 | CN1565606A Chinese drug with functions of regulating blood lipid and treating cardiovascular and cerebrovascular disease |
| 01/19/2005 | CN1565605A Diabetes treating pharmaceutical compositions and its preparing method |
| 01/19/2005 | CN1565602A Blood sugar reducing tea for treating diabetes and its preparing method |
| 01/19/2005 | CN1565583A Chinese drugs compositions for treating diabetes and its complications |
| 01/19/2005 | CN1565554A Fat reducing Chinese drugs for treating simple obesity |
| 01/19/2005 | CN1565542A Blood pressure reducing and blood fat removing healthy compositions |
| 01/19/2005 | CN1565512A Blood sugar decreasing Chinese herbal medicine for treating SARS patients with diabetes complication |
| 01/19/2005 | CN1565502A Novel formulation of 'GuiFu Dihuang' and its preparing method |
| 01/19/2005 | CN1565497A Hypertension lowering and blood fat reducing tea and its preparation |
| 01/19/2005 | CN1565472A Breviscapine slow release microsphere medicine formulation |
| 01/19/2005 | CN1565467A Use of cornel and its extract in preparation alpha-glucosidase inhibitor medicine |
| 01/19/2005 | CN1565461A Use of stachyose in preparing drug for diabetes and its preparation method |
| 01/19/2005 | CN1565453A 6-amino-ª‡(R)-hydroxyl-9H-purin-9-ethyl butyrate immunological suppression effect |
| 01/19/2005 | CN1565449A Pyrroloquinoline containing composition for enriching zinc and reducing plumbum |
| 01/19/2005 | CN1565423A Ultra fine egg shell powder preparation method |
| 01/19/2005 | CN1565420A Oral nano nourishing emulsion and its preparation method |
| 01/19/2005 | CN1185258C Trivalent chromium composition and its use |
| 01/19/2005 | CN1185257C Glucagon insulinotropic complexes, compositions and methods |
| 01/19/2005 | CN1185250C Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 01/19/2005 | CN1185233C Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 01/19/2005 | CN1185232C Inhibitors of alpha L beta 2 mediated cell adhesion |
| 01/19/2005 | CN1185229C 3-indolyl-4-phenyl-1H-pyrrole-2, 5-dione derivatives as inhibitors of glycogen synthase kinase-3beta |
| 01/19/2005 | CN1185220C Para-amino substituted phenylamide glucokinase activators |